About Us

About Us


The Egyptian Pharmaceutical Vigilance Center (EPVC) has been established at the Central Administration for Pharmaceutical Affairs (CAPA)-Ministry of Health & Population December 2009 according to the ministerial decree 368/2012.

The center is responsible for collection, evaluation and assessment of information about the safety of pharmaceutical products including (Medicinal products, Biological Biocides, herbal medicines, Cosmetics, Veterinary products, medical devices and Biocides) authorized in Egypt

The center is divided into Pharmacovigilance department, Medical Device safety Department & Biocides Vigilance Department.

Cosmetics and Veterinary Vigilance departments are under construction.

Regional Centers have been established in Alexandria, Cairo and Sohag

Vision

To achieve a well-structured Pharmacovigilance center with highly trained personnel that is nationally competent and regionally recognized.

Mission

  1. Improve patient care and safety in relation to the use of medicines and all medical and paramedical interventions.
  2. Improve public health and safety in relation to the use of medicines.
  3. Detect problems related to the use of medicines and communicate the findings in a timely manner.
  4. To contribute to the assessment of the risk-benefit profile of medicines, thus encouraging safer and more effective use of medicines.
  5. Promote understanding, education and clinical training in Pharmacovigilance and its effective communication to the public.

Objectives of the center

  1. Enhance patient care and patient safety in relation to the use of medicines, especially with regard to the prevention of unintended harm from the use of drugs.
  2. Improve public health and safety in relation to the use of medicines by the provision of reliable, balanced information resulting in more rational use of drugs.
  3. Contribute to the assessment of the risk-benefit profile of medicines, thus encouraging safer and more effective use of medicines and a resolution of the sometimes apparently conflicting interests of public health and individual patient welfare.

Aim of the Center

  1. Early detection of adverse drug reactions (ADRs).
  2. Detection of increased frequency of ADRs.
  3. Identification of predictors and possible mechanisms underlying ADRs.
  4. Quantitative Estimation of risk/benefit profiles of drugs and dissemination of information needed to improve drug prescribing and regulation.
  5. Prevention of preventable ADRs.
  6. Encouraging rational and safe use of drugs.
  7. Communication and dissemination with international institutions working in Pharmacovigilance.